Watch: Why Zilico chose Manchester to expand & access finance

Share

Cancer has long been a focus of R&D investment for the medtech and pharma industries, and will no doubt continue to be for many years to come. With early and accurate detection key to survival rates, improved diagnostics is a real area of interest.

One of our customers already making a global impact in this area is Zilico, a medtech medical device diagnostics business, which has developed a more accurate means of diagnosis for cervical intraepithelial neoplasia (CIN), the precursor to cervical cancer.

Zilico have developed the ZedScan™  - a portable, handheld device that uses patented Electrical Impedance Spectroscopy (EIS) to detect the development of CIN and cancer. For clinicians it helps better manage patients as it delivers a more accurate diagnosis. For healthcare providers, it will help better manage colposcopy referrals especially after the introduction of primary HPV testing, and overall ensure better outcomes for patients.

Learn more about Zilico’s journey with MSP on the video below.